Latest Insider Transactions at Eli Lilly & CO (LLY)
This section provides a real-time view of insider transactions for Eli Lilly & CO (LLY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ELI LILLY & Co to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ELI LILLY & Co's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 11
2018
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
140,000
-0.11%
|
$11,340,000
$81.97 P/Share
|
|
May 03
2018
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
SELL
Open market or private sale
|
Direct |
9,027
-6.25%
|
$704,106
$78.5 P/Share
|
|
May 01
2018
|
Enrique A Conterno SVP&Pres, LillyDiab & LillyUSA |
SELL
Payment of exercise price or tax liability
|
Direct |
8,934
-5.64%
|
$723,654
$81.07 P/Share
|
|
May 01
2018
|
Enrique A Conterno SVP&Pres, LillyDiab & LillyUSA |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+11.21%
|
-
|
|
May 01
2018
|
Christi Shaw SVP and Pres., Lilly Bio-Meds |
SELL
Payment of exercise price or tax liability
|
Direct |
5,324
-38.72%
|
$431,244
$81.07 P/Share
|
|
May 01
2018
|
Christi Shaw SVP and Pres., Lilly Bio-Meds |
BUY
Exercise of conversion of derivative security
|
Direct |
13,750
+50.0%
|
-
|
|
May 01
2018
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
SELL
Payment of exercise price or tax liability
|
Direct |
8,716
-5.69%
|
$705,996
$81.07 P/Share
|
|
May 01
2018
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+11.55%
|
-
|
|
Apr 25
2018
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
180,000
-0.07%
|
$14,580,000
$81.21 P/Share
|
|
Apr 16
2018
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
136
+0.34%
|
$10,880
$80.12 P/Share
|
|
Apr 16
2018
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
68
+0.12%
|
$5,440
$80.12 P/Share
|
|
Apr 16
2018
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
121
+2.03%
|
$9,680
$80.12 P/Share
|
|
Apr 16
2018
|
Susan Mahony SVP & Pres., Lilly Oncology |
SELL
Open market or private sale
|
Direct |
17,379
-38.07%
|
$1,390,320
$80.08 P/Share
|
|
Apr 13
2018
|
Susan Mahony SVP & Pres., Lilly Oncology |
SELL
Open market or private sale
|
Direct |
5,165
-10.16%
|
$413,200
$80.14 P/Share
|
|
Mar 19
2018
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
139
+0.34%
|
$10,842
$78.57 P/Share
|
|
Mar 19
2018
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
69
+0.12%
|
$5,382
$78.57 P/Share
|
|
Mar 19
2018
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
123
+2.11%
|
$9,594
$78.57 P/Share
|
|
Mar 16
2018
|
Joshua L Smiley |
SELL
Open market or private sale
|
Direct |
3,000
-13.03%
|
$237,000
$79.2 P/Share
|
|
Mar 01
2018
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Open market or private sale
|
Indirect |
860
-34.44%
|
$65,360
$76.5 P/Share
|
|
Feb 21
2018
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Open market or private sale
|
Indirect |
876
-26.16%
|
$67,452
$77.55 P/Share
|
|
Feb 20
2018
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
141
+0.35%
|
$10,857
$77.55 P/Share
|
|
Feb 20
2018
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
70
+0.12%
|
$5,390
$77.55 P/Share
|
|
Feb 20
2018
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
125
+2.2%
|
$9,625
$77.55 P/Share
|
|
Feb 16
2018
|
Johna Norton EVP, Global Quality |
SELL
Payment of exercise price or tax liability
|
Indirect |
14
-29.17%
|
$1,092
$78.02 P/Share
|
|
Feb 16
2018
|
Johna Norton EVP, Global Quality |
BUY
Exercise of conversion of derivative security
|
Indirect |
48
+50.0%
|
-
|
|
Feb 05
2018
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Open market or private sale
|
Direct |
900
-17.89%
|
$72,900
$81.09 P/Share
|
|
Feb 05
2018
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
SELL
Open market or private sale
|
Direct |
9,625
-6.74%
|
$779,625
$81.12 P/Share
|
|
Feb 01
2018
|
Myles O'Neill SVP & Pres., Mfg. Operations |
SELL
Payment of exercise price or tax liability
|
Indirect |
4,280
-5.33%
|
$346,680
$81.45 P/Share
|
|
Feb 01
2018
|
Myles O'Neill SVP & Pres., Mfg. Operations |
BUY
Exercise of conversion of derivative security
|
Indirect |
9,596
+10.68%
|
-
|
|
Feb 01
2018
|
Melissa S Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
SELL
Payment of exercise price or tax liability
|
Direct |
2,789
-12.62%
|
$225,909
$81.45 P/Share
|
|
Feb 01
2018
|
Melissa S Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
BUY
Exercise of conversion of derivative security
|
Direct |
6,398
+22.45%
|
-
|
|
Feb 01
2018
|
Enrique A Conterno SVP&Pres, LillyDiab & LillyUSA |
SELL
Payment of exercise price or tax liability
|
Direct |
9,512
-6.43%
|
$770,472
$81.45 P/Share
|
|
Feb 01
2018
|
Enrique A Conterno SVP&Pres, LillyDiab & LillyUSA |
BUY
Exercise of conversion of derivative security
|
Direct |
21,326
+12.6%
|
-
|
|
Feb 01
2018
|
Stephen F Fry SVP, HR & Diversity |
SELL
Payment of exercise price or tax liability
|
Direct |
7,609
-7.06%
|
$616,329
$81.45 P/Share
|
|
Feb 01
2018
|
Stephen F Fry SVP, HR & Diversity |
BUY
Exercise of conversion of derivative security
|
Direct |
17,060
+13.66%
|
-
|
|
Feb 01
2018
|
Michael J Harrington Senior VP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
10,811
-10.52%
|
$875,691
$81.45 P/Share
|
|
Feb 01
2018
|
Michael J Harrington Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
24,524
+19.27%
|
-
|
|
Feb 01
2018
|
Jan M Lundberg EVP,Science&Tech and Pres. LRL |
SELL
Payment of exercise price or tax liability
|
Direct |
16,169
-7.55%
|
$1,309,689
$81.45 P/Share
|
|
Feb 01
2018
|
Jan M Lundberg EVP,Science&Tech and Pres. LRL |
BUY
Exercise of conversion of derivative security
|
Direct |
36,252
+14.47%
|
-
|
|
Feb 01
2018
|
Susan Mahony SVP & Pres., Lilly Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
9,533
-15.8%
|
$772,173
$81.45 P/Share
|
|
Feb 01
2018
|
Susan Mahony SVP & Pres., Lilly Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
21,326
+26.11%
|
-
|
|
Feb 01
2018
|
David A Ricks President, Chair, and CEO |
SELL
Bona fide gift
|
Direct |
11,764
-8.96%
|
-
|
|
Feb 01
2018
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,559
-6.79%
|
$774,279
$81.45 P/Share
|
|
Feb 01
2018
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,326
+13.15%
|
-
|
|
Feb 01
2018
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
SELL
Payment of exercise price or tax liability
|
Direct |
7,133
-10.91%
|
$577,773
$81.45 P/Share
|
|
Feb 01
2018
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
BUY
Exercise of conversion of derivative security
|
Direct |
15,993
+19.66%
|
-
|
|
Feb 01
2018
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
SELL
Payment of exercise price or tax liability
|
Direct |
9,294
-6.11%
|
$752,814
$81.45 P/Share
|
|
Feb 01
2018
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
BUY
Exercise of conversion of derivative security
|
Direct |
21,326
+12.3%
|
-
|
|
Jan 29
2018
|
Myles O'Neill SVP & Pres., Mfg. Operations |
BUY
Grant, award, or other acquisition
|
Indirect |
4,279
+5.71%
|
$372,273
$87.6 P/Share
|
|
Jan 29
2018
|
Melissa S Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
BUY
Grant, award, or other acquisition
|
Direct |
3,759
+19.31%
|
$327,033
$87.6 P/Share
|